APOM

Summary

APOM (apolipoprotein M, HGNC:13916) is a protein-coding gene on chromosome 6p21.33, encoding Apolipoprotein M (O95445). Probably involved in lipid transport.

The protein encoded by this gene is an apolipoprotein and member of the lipocalin protein family. It is found associated with high density lipoproteins and to a lesser extent with low density lipoproteins and triglyceride-rich lipoproteins. The encoded protein is secreted through the plasma membrane but remains membrane-bound, where it is involved in lipid transport. Alternate splicing results in both coding and non-coding variants of this gene.

Source: NCBI Gene 55937 — RefSeq curated summary.

At a glance

• GWAS associations: 31
• Clinical variants (ClinVar): 21 total
• MANE Select transcript: NM_019101

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13916
Approved symbol	APOM
Name	apolipoprotein M
Location	6p21.33
Locus type	gene with protein product
Status	Approved
Aliases	G3a, NG20, Apo-M
Ensembl gene	ENSG00000204444
Ensembl biotype	protein_coding
OMIM	606907
Entrez	55937

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 3 protein_coding

ENST00000375916, ENST00000375918, ENST00000375920

RefSeq mRNA: 2 — MANE Select: NM_019101 NM_001256169, NM_019101

CCDS: CCDS4710, CCDS59004

Canonical transcript exons

ENST00000375916 — 6 exons

Exon	Start	End
ENSE00001629159	31657225	31657298
ENSE00001694738	31657625	31657723
ENSE00001747435	31657380	31657478
ENSE00001773377	31658064	31658210
ENSE00001834054	31655894	31656080
ENSE00003491289	31656472	31656626

Expression profiles

Bgee: expression breadth ubiquitous, 132 present calls, max score 99.05.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 5.2708 / max 163.3578, expressed in 1565 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
67003	2.4994	1278
67002	1.4634	855
67006	0.6137	69
67007	0.4448	61
67008	0.1185	46
67004	0.1026	34
203946	0.0283	17

Top tissues by expression

133 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right lobe of liver	UBERON:0001114	99.05	gold quality
liver	UBERON:0002107	98.56	gold quality
adult mammalian kidney	UBERON:0000082	95.52	gold quality
kidney	UBERON:0002113	91.95	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	88.21	gold quality
cortex of kidney	UBERON:0001225	85.70	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	85.69	gold quality
metanephros cortex	UBERON:0010533	83.47	gold quality
left testis	UBERON:0004533	82.67	gold quality
testis	UBERON:0000473	82.31	gold quality
right testis	UBERON:0004534	82.29	gold quality
small intestine Peyer’s patch	UBERON:0003454	78.96	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	78.65	gold quality
small intestine	UBERON:0002108	77.93	gold quality
gastrocnemius	UBERON:0001388	77.70	gold quality
muscle of leg	UBERON:0001383	77.52	gold quality
bone marrow	UBERON:0002371	77.35	gold quality
ganglionic eminence	UBERON:0004023	77.29	gold quality
hindlimb stylopod muscle	UBERON:0004252	77.11	gold quality
blood	UBERON:0000178	76.86	gold quality
ventricular zone	UBERON:0003053	76.72	gold quality
monocyte	CL:0000576	76.42	gold quality
leukocyte	CL:0000738	76.42	gold quality
body of pancreas	UBERON:0001150	76.05	gold quality
right adrenal gland	UBERON:0001233	76.00	gold quality
substantia nigra	UBERON:0002038	75.92	gold quality
granulocyte	CL:0000094	75.81	gold quality
left adrenal gland	UBERON:0001234	75.60	gold quality
skin of leg	UBERON:0001511	75.60	gold quality
left adrenal gland cortex	UBERON:0035825	75.57	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-MTAB-9388	yes	11.71
E-MTAB-6058	no	21.51
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AP1, FOXA2, FOXC1, HNF1A, HNF4A, JUN, JUNB, NR0B2, NR4A2, NR5A2, PPARD, PPARG, SPI1

miRNA regulators (miRDB)

15 targeting APOM, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-4745-5P	99.98	65.95	1028
HSA-MIR-4487	99.96	64.58	1252
HSA-MIR-4700-5P	98.63	67.43	1915
HSA-MIR-8089	97.74	66.21	1698
HSA-MIR-4667-5P	97.61	66.67	1683
HSA-MIR-6736-3P	96.98	65.22	1342
HSA-MIR-4652-5P	96.46	64.22	553
HSA-MIR-920	95.97	63.95	811
HSA-MIR-6726-5P	95.97	63.72	841
HSA-MIR-4300	95.85	64.56	1003
HSA-MIR-5591-5P	95.85	64.76	1002
HSA-MIR-365A-5P	94.91	63.72	471
HSA-MIR-365B-5P	94.91	63.79	470

Literature-anchored findings (GeneRIF, showing 40)

• HNF-1alpha is required for apoM expression in vivo, and heterozygous HNF-1alpha mutations lead to HNF-1alpha-dependent impairment of apoM expression. (PMID:14633861)
• During human embryogenesis, apoM was mainly expressed in liver and kidney and little was found in small intestine (PMID:15147633)
• we excluded APOM as a genetic determinant of Alzheimer disease in our large French case control population. (PMID:15172102)
• results show that Apolipoprotein M (apoM) is positively related to leptin and negatively related to cholesterol in humans (PMID:15542348)
• Results show that leptin does not significantly influence the expression of apolipoproteins AI, B and E in HepG2 cells, suggesting that leptin has a specific regulatory effect on hepatic apoM transcription and secretion in vitro. (PMID:15904876)
• study provided the first evidence that SNP T-778C in the proximal promoter region of apoM was associated with the levels of plasma cholesterol & fasting plasma glucose & also conferred risk in development of type 2 diabetes in Han Chinese (PMID:16572495)
• Results suggest that apoM is associated with a small heterogeneous subpopulation of HDL particles. (PMID:16682745)
• We demonstrated the presence of five isoforms of apo M in LDL: three that are both N-glycosylated and sialylated, one that is N-glycosylated but not sialylated, and one that is neither N-glycosylated nor sialylated. (PMID:17022639)
• Hepatic apoM expression is significantly influenced by the acute phase of hepatic ischemia-reperfusion injury. (PMID:17112825)
• the binding of retinol and retinoic acid supports the hypothesis that apoM is a lipocalin. (PMID:17525477)
• The apoM gene is a risk factor for genetic susceptibility to coronary artery disease and is also associated with total cholesterol levels in Han Chinese. (PMID:17674965)
• results of the present study suggest that the APOM T-855C polymorphism carries an increased risk for coronary artery disease in this Chinese population (PMID:17973931)
• APOM transcription is regulated by LRH-1 (PMID:17977826)
• In the setting of low density lipoprotein receptor deficiency, apoM-Tg mice with approximately 2-fold increased plasma apoM concentrations developed smaller atherosclerotic lesions than controls. (PMID:18006500)
• Apolipoprotein M is a negative acute response protein that decreases during infection and inflammation (PMID:18054359)
• This strongly indicates that the signal peptide is indeed necessary for apoM’s ability to associate with lipid. (PMID:18279674)
• Foxa2 activity increases plasma high density lipoprotein levels by regulating apolipoprotein M (PMID:18381283)
• The signal peptide anchors apolipoprotein M in plasma lipoproteins and prevents rapid clearance of apolipoprotein M from plasma (PMID:18460466)
• In conditional logistic regression analyses, apoM was not a predictor of CHD events. (PMID:18490703)
• plasma apoM levels in hepatocellular carcinoma patients were significantly increased than those in the normal subjects, but lower than those in the chronic hepatitis and cirrhosis patients (PMID:18652652)
• Data show that Allele C of SNP T-778C in Apolipoprotein M promoter may increase promoter activity and confer the risk susceptibility to the development of T1D. (PMID:19007767)
• The findings suggest that ApoM could not be an independent risk factor but a biomarker of coronary artery disease. (PMID:19100249)
• ApoM plays a part in lipoprotein metabolism; however, the biological impact of apoM in humans remains to be determined. (PMID:19200746)
• Plasma apoM is reduced in metabolic syndrome (PMID:19539616)
• Results describe the crystal structure of recombinant human apoM and show that apoM, although refolded from inclusion bodies, was in complex with fatty acids containing 14, 16 or 18 carbon atoms. (PMID:19733574)
• ApoM may function catalytically at an intracellular site to transfer lipid onto pre beta HDL during or after their formation by ABCA1. (PMID:19767535)
• hepatocellular carcinoma tissues had a reduced capacity to produce apoM than the adjacent non-tumor tissues (PMID:19796793)
• ApoA-I, apoB and apoM levels were significantly lower in patients with abdominal aortic aneurysm than in the control individuals. (PMID:19932694)
• In subjects with critical limb ischemia (CLI), plasma concentrations of apoA-I, apoB and apoM were significantly lower than in control individuals, but only apoA-I was independently associated to CLI. (PMID:20080084)
• Regulation of human apolipoprotein m gene expression by orphan and ligand-dependent nuclear receptors. (PMID:20660599)
• ApoM metabolism is to a considerable extent independent of statin- and fibrate-affected pathways involved in cholesterol homeostasis (PMID:20828695)
• ApoM is expressed in human colorectal tissues: comparison of expression in normal tissue/mucosa, adenocarcinoma (w/ or w/o lymphatic metastasis), polyps, and inflammatory mucosa. (PMID:20846402)
• Data demonstrate that ApoM T-778 C and C-1065A single-nucleotide polymorphisms were associated with increased risk of ischemic stroke in a Han Chinese population. (PMID:20872094)
• The PCSK9 pathway may contribute to plasma apoM regulation in humans. The influence of PCSK9 on circulating apoM appears to be modified by adiposity. (PMID:21122852)
• Apolipoprotein M gene (APOM) polymorphism modifies metabolic and disease traits in type 2 diabetes. (PMID:21390319)
• the human apolipoprotein M gene is regulated in opposite ways by hepatocyte nuclear factor 1 and Jun transcription factors (PMID:21454713)
• Results show that apoM, by delivering S1P to the S1P(1) receptor on endothelial cells, is a vasculoprotective constituent of HDL. (PMID:21606363)
• Single Nucleotide Polymorphism at the promoter region of the APOM gene is associated with rheumatoid arthritis. (PMID:21844665)
• Raised ApoM levels in hepatitis B virus (HBV) infection may in turn suppress HBV replication (PMID:21875437)
• Report plasma levels of sphingosine-1-phosphate and apolipoprotein M in patients with monogenic disorders of HDL metabolism. (PMID:21944699)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Apom	ENSMUSG00000024391
rattus_norvegicus	Apom	ENSRNOG00000000850

Protein

Protein identifiers

Apolipoprotein M — O95445 (reviewed: O95445)

Alternative names: Protein G3a

All UniProt accessions (3): A0A1U9X793, O95445, Q5SRP5

UniProt curated annotations — full annotation on UniProt →

Function. Probably involved in lipid transport. Can bind sphingosine-1-phosphate, myristic acid, palmitic acid and stearic acid, retinol, all-trans-retinoic acid and 9-cis-retinoic acid.

Subunit / interactions. Interacts with LRP2; LRP2 mediates APOM renal uptake and subsequent lysosomal degradation.

Subcellular location. Secreted.

Tissue specificity. Plasma protein. Expressed in liver and kidney.

Similarity. Belongs to the calycin superfamily. Lipocalin family. Highly divergent.

Isoforms (2)

UniProt ID	Names	Canonical?
O95445-1	1	yes
O95445-2	2

RefSeq proteins (2): NP_001243098, NP_061974* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR012674	Calycin	Homologous_superfamily
IPR022734	ApoM	Family

Pfam: PF11032

UniProt features (27 total): strand 9, helix 4, mutagenesis site 3, disulfide bond 3, sequence conflict 2, binding site 2, chain 1, signal peptide 1, glycosylation site 1, splice variant 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
2YG2	X-RAY DIFFRACTION	1.7
2WEW	X-RAY DIFFRACTION	1.95
2WEX	X-RAY DIFFRACTION	2

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O95445-F1	89.61	0.68

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (2): 136; 143

Disulfide bonds (3): 23–167, 95–183, 128–157

Glycosylation sites (1): 135

Mutagenesis-validated functional residues (3):

Position	Phenotype
135	loss of glycosylation.
148	no loss of glycosylation.
22	introduces a signal cleavage site. abolishes interaction with lipoprotein particles. leads to rapid elimination from pla

Function

Pathways and Gene Ontology

Reactome pathways

6 pathways

ID	Pathway
R-HSA-975634	Retinoid metabolism and transport
R-HSA-1430728	Metabolism
R-HSA-196854	Metabolism of vitamins and cofactors
R-HSA-2187338	Visual phototransduction
R-HSA-6806667	Metabolism of fat-soluble vitamins
R-HSA-9709957	Sensory Perception

MSigDB gene sets: 144 (showing top): GOBP_STEROL_HOMEOSTASIS, GOBP_LIPOPROTEIN_METABOLIC_PROCESS, MODULE_45, HNF1_Q6, GOBP_PROTEIN_LIPID_COMPLEX_ASSEMBLY, COUP_01, GOBP_ORGANIC_HYDROXY_COMPOUND_TRANSPORT, GOBP_NEGATIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION, GOBP_LIPID_HOMEOSTASIS, GOBP_CHOLESTEROL_EFFLUX, GOBP_NEGATIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS, GOBP_PLASMA_LIPOPROTEIN_PARTICLE_CLEARANCE, LI_WILMS_TUMOR_VS_FETAL_KIDNEY_1_UP, GOBP_CELLULAR_RESPONSE_TO_TOXIC_SUBSTANCE, RGTTAMWNATT_HNF1_01

GO Biological Process (10): cholesterol efflux (GO:0033344), high-density lipoprotein particle remodeling (GO:0034375), high-density lipoprotein particle assembly (GO:0034380), high-density lipoprotein particle clearance (GO:0034384), negative regulation of plasma lipoprotein oxidation (GO:0034445), lipoprotein metabolic process (GO:0042157), cholesterol homeostasis (GO:0042632), reverse cholesterol transport (GO:0043691), lipid transport (GO:0006869), cellular oxidant detoxification (GO:0098869)

GO Molecular Function (3): lipid carrier activity (GO:0005319), phospholipid binding (GO:0005543), antioxidant activity (GO:0016209)

GO Cellular Component (7): extracellular region (GO:0005576), very-low-density lipoprotein particle (GO:0034361), low-density lipoprotein particle (GO:0034362), high-density lipoprotein particle (GO:0034364), discoidal high-density lipoprotein particle (GO:0034365), spherical high-density lipoprotein particle (GO:0034366), obsolete extracellular space (GO:0005615)

Reactome top-level categories

Rollup of top-5 pathways:

Category	Pathways
Visual phototransduction	1
Metabolism of fat-soluble vitamins	1
Metabolism	1
Sensory Perception	1
Metabolism of vitamins and cofactors	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cholesterol transport	2
plasma lipoprotein particle	2
high-density lipoprotein particle	2
plasma lipoprotein particle remodeling	1
plasma lipoprotein particle assembly	1
plasma lipoprotein particle clearance	1
plasma lipoprotein particle oxidation	1
regulation of plasma lipoprotein oxidation	1
negative regulation of cellular component organization	1
negative regulation of multicellular organismal process	1
protein metabolic process	1
sterol homeostasis	1
transport	1
lipid localization	1
cellular detoxification	1
molecular carrier activity	1
lipid binding	1
molecular_function	1
cellular oxidant detoxification	1
cellular anatomical structure	1
triglyceride-rich plasma lipoprotein particle	1

Protein interactions and networks

STRING

1088 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
APOM	GPANK1	O95872	967
APOM	APOA2	P02652	856
APOM	S1PR2	O95136	853
APOM	APOA4	P06727	824
APOM	APOA1	P02647	819
APOM	APOE	P02649	797
APOM	APOD	P05090	785
APOM	APOC1	P02654	776
APOM	APOA5	Q6Q788	773
APOM	APOC3	P02656	768
APOM	APOC2	P02655	766
APOM	APOF	Q13790	765
APOM	CLU	P10909	751
APOM	APOL1	O14791	740
APOM	APOH	P02749	721

IntAct

12 interactions, top by confidence:

A	B	Type	Score
SEC11C	APOM	psi-mi:“MI:0914”(association)	0.530
APOM	HLA-A	psi-mi:“MI:0914”(association)	0.350
APOM	CT45A8	psi-mi:“MI:0914”(association)	0.350
APOM	ESYT2	psi-mi:“MI:0914”(association)	0.350
APOM	DST	psi-mi:“MI:0914”(association)	0.350
GPC3	PXDNL	psi-mi:“MI:0914”(association)	0.350
		psi-mi:“MI:0914”(association)	0.350
KLF6	APOM	psi-mi:“MI:0915”(physical association)	0.000
C8orf30A	APOM	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (48): CT45A2 (Affinity Capture-MS), USP16 (Affinity Capture-MS), APOM (Affinity Capture-MS), CNTNAP3 (Affinity Capture-MS), CDYL (Affinity Capture-MS), APOM (Two-hybrid), APOM (Two-hybrid), APOM (Affinity Capture-MS), USP16 (Affinity Capture-MS), CT45A2 (Affinity Capture-MS), ADAM21 (Affinity Capture-MS), CLSTN3 (Affinity Capture-MS), GPX8 (Affinity Capture-MS), CNNM3 (Affinity Capture-MS), HS6ST1 (Affinity Capture-MS)

ESM2 similar proteins: A2AEP0, A2AJB7, M5AXY1, O18874, O95445, P00978, P02753, P02763, P02764, P04916, P04939, P06910, P06911, P06912, P07361, P09465, P11944, P14630, P19652, P21350, P21352, P21760, P27485, P35578, P36992, P41263, P61641, P81608, Q00724, Q07456, Q28369, Q28388, Q29147, Q29614, Q2LE37, Q3SZR3, Q5R894, Q5VFH6, Q60559, Q60590

Diamond homologs: O95445, P14630, Q2LE37, Q5R894, Q9Z1R3

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

21 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	10
Likely benign	3
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

702 predictions. Top by Δscore:

Variant	Effect	Δscore
6:31656631:GTG:G	donor_gain	1.0000
6:31657475:TACA:T	donor_gain	1.0000
6:31657477:CA:C	donor_gain	1.0000
6:31657479:G:GG	donor_gain	1.0000
6:31657483:G:GG	donor_gain	1.0000
6:31657622:CAGA:C	acceptor_loss	1.0000
6:31657623:A:AG	acceptor_gain	1.0000
6:31657624:G:GG	acceptor_gain	1.0000
6:31657624:GATC:G	acceptor_gain	1.0000
6:31656470:A:AG	acceptor_gain	0.9900
6:31656471:G:GG	acceptor_gain	0.9900
6:31656623:GCAT:G	donor_gain	0.9900
6:31656627:G:GG	donor_gain	0.9900
6:31656629:GAGTG:G	donor_gain	0.9900
6:31657205:T:TA	acceptor_gain	0.9900
6:31657209:A:AG	acceptor_gain	0.9900
6:31657210:C:G	acceptor_gain	0.9900
6:31657212:A:AG	acceptor_gain	0.9900
6:31657213:C:G	acceptor_gain	0.9900
6:31657215:A:AG	acceptor_gain	0.9900
6:31657216:C:G	acceptor_gain	0.9900
6:31657220:TGCA:T	acceptor_loss	0.9900
6:31657221:GCA:G	acceptor_loss	0.9900
6:31657223:A:AT	acceptor_loss	0.9900
6:31657224:G:A	acceptor_loss	0.9900
6:31657224:GGAAA:G	acceptor_gain	0.9900
6:31657275:G:GT	donor_gain	0.9900
6:31657376:ACAGG:A	acceptor_loss	0.9900
6:31657377:CAGGC:C	acceptor_loss	0.9900
6:31657378:A:AG	acceptor_gain	0.9900

AlphaMissense

1239 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:31657255:G:C	W100C	0.994
6:31657255:G:T	W100C	0.994
6:31656496:T:A	W47R	0.990
6:31656496:T:C	W47R	0.990
6:31657253:T:A	W100R	0.990
6:31657253:T:C	W100R	0.990
6:31656498:G:C	W47C	0.985
6:31656498:G:T	W47C	0.985
6:31656508:G:C	A51P	0.984
6:31656545:T:G	F63C	0.983
6:31657287:T:C	L111P	0.983
6:31656544:T:C	F63L	0.982
6:31656546:T:A	F63L	0.982
6:31656546:T:G	F63L	0.982
6:31656502:T:C	F49L	0.981
6:31656504:T:A	F49L	0.981
6:31656504:T:G	F49L	0.981
6:31657437:T:C	L134P	0.981
6:31656568:T:C	F71L	0.980
6:31656570:C:A	F71L	0.980
6:31656570:C:G	F71L	0.980
6:31657470:T:C	L145P	0.979
6:31657663:T:C	F161L	0.979
6:31657664:T:C	F161S	0.979
6:31657665:C:A	F161L	0.979
6:31657665:C:G	F161L	0.979
6:31656514:G:C	A53P	0.978
6:31657475:T:G	Y147D	0.978
6:31656503:T:C	F49S	0.977
6:31656623:G:C	R89P	0.977

dbSNP variants (sampled 300 via entrez): RS1000107232 (6:31653962 T>G), RS1001164231 (6:31652319 A>C), RS1001492417 (6:31652661 C>A), RS1001781736 (6:31655079 C>T), RS1002778502 (6:31654294 T>C), RS1002863890 (6:31656183 G>C), RS1003240910 (6:31654581 T>C), RS1003454247 (6:31656934 C>G,T), RS1003739612 (6:31650479 C>A,G,T), RS1003806338 (6:31656885 G>A), RS1003859566 (6:31657993 C>G,T), RS1004403111 (6:31650438 G>A,C), RS1005075513 (6:31654748 A>G), RS1005421656 (6:31650922 A>G), RS1005477810 (6:31658629 C>T)

Disease associations

OMIM: gene MIM:606907 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

31 associations (top):

Study	Trait	p-value
GCST000506_1	Lung adenocarcinoma	5.000000e-12
GCST001203_1	Rheumatoid arthritis	3.000000e-10
GCST004131_25	Inflammatory bowel disease	2.000000e-31
GCST004133_79	Ulcerative colitis	5.000000e-65
GCST004521_114	Autism spectrum disorder or schizophrenia	3.000000e-17
GCST004521_117	Autism spectrum disorder or schizophrenia	3.000000e-15
GCST004521_126	Autism spectrum disorder or schizophrenia	2.000000e-10
GCST004521_154	Autism spectrum disorder or schizophrenia	3.000000e-08
GCST004521_17	Autism spectrum disorder or schizophrenia	2.000000e-12
GCST004521_209	Autism spectrum disorder or schizophrenia	5.000000e-16
GCST004521_211	Autism spectrum disorder or schizophrenia	5.000000e-15
GCST004521_213	Autism spectrum disorder or schizophrenia	5.000000e-13
GCST004521_224	Autism spectrum disorder or schizophrenia	5.000000e-10
GCST004521_227	Autism spectrum disorder or schizophrenia	4.000000e-12
GCST004521_265	Autism spectrum disorder or schizophrenia	7.000000e-14
GCST004521_281	Autism spectrum disorder or schizophrenia	5.000000e-09
GCST004521_45	Autism spectrum disorder or schizophrenia	2.000000e-16
GCST004521_70	Autism spectrum disorder or schizophrenia	8.000000e-20
GCST004521_81	Autism spectrum disorder or schizophrenia	1.000000e-14
GCST004748_109	Lung cancer	9.000000e-19
GCST004749_5	Lung cancer in ever smokers	4.000000e-14
GCST004750_57	Squamous cell lung carcinoma	8.000000e-18
GCST005541_17	Sarcoidosis (Lofgren’s syndrome vs non-Lofgren’s syndrome)	1.000000e-30
GCST006585_631	Blood protein levels	3.000000e-06
GCST008916_111	Asthma	2.000000e-14
GCST008916_114	Asthma	1.000000e-09
GCST008916_30	Asthma	1.000000e-09
GCST008917_2	Asthma (childhood onset)	4.000000e-07
GCST008921_1	Asthma and major depressive disorder	2.000000e-16
GCST010725_43	Malaria	5.000000e-07

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

46 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression	4
bisphenol A	increases expression, decreases reaction, increases abundance, affects expression, affects cotreatment (+1 more)	3
Benzo(a)pyrene	affects methylation, decreases expression	2
Dimethyl Sulfoxide	affects expression, decreases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Quercetin	affects cotreatment, decreases expression	2
Cyclosporine	decreases expression	2
Simvastatin	decreases expression, increases expression, decreases reaction	2
ginger extract	increases expression, decreases reaction, increases abundance	1
urushiol	decreases expression	1
methylmercuric chloride	decreases expression	1
methyleugenol	decreases expression	1
triphenyl phosphate	affects expression	1
sodium arsenate	decreases expression, increases abundance	1
decabromobiphenyl ether	affects expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
tanshinone	increases expression	1
benazol P	affects expression	1
ciglitazone	affects binding, increases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
corosolic acid	increases expression	1
T0901317	decreases reaction, increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
bisphenol S	decreases methylation	1
2,3,5-trichloro-6-phenyl-(1,4)benzoquinone	decreases expression	1
Sunitinib	increases expression	1
Fulvestrant	affects cotreatment, increases methylation	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.